Form 8-K - Current report:
SEC Accession No. 0001493152-24-035144
Filing Date
2024-09-05
Accepted
2024-09-05 16:05:35
Documents
16
Period of Report
2024-09-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40247
2 ex99-1.htm EX-99.1 15331
3 ex99-1_001.jpg GRAPHIC 3265
  Complete submission text file 0001493152-24-035144.txt   278584

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20240904.xsd EX-101.SCH 3519
5 XBRL DEFINITION FILE lixt-20240904_def.xml EX-101.DEF 26564
6 XBRL LABEL FILE lixt-20240904_lab.xml EX-101.LAB 36548
7 XBRL PRESENTATION FILE lixt-20240904_pre.xml EX-101.PRE 25188
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5396
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 241281417
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)